This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.
Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
HMB is produced naturally in our bodies during the metabolism of the essential amino acid leucine. While many of HMB’s ...
Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...
Woman's World on MSN1d
Looking To Come Off GLP-1 Injectables? Try Calocurb, a Natural Appetite Suppressant, Instead!Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback